>Marché des taxanes au Moyen-Orient et en Afrique, par type (paclitaxel, docétaxel, cabazitaxel), type de médicament (génériques, de marque), formulation (liposomes, nanoparticules , micelles polymères, autres), groupe d'âge (adultes, gériatrique), application (cancer du sein, cancer du poumon non à petites cellules, cancer du pancréas, cancer de l'ovaire, cancer de la prostate, autres), utilisateur final (hôpitaux, centres de chirurgie ambulatoire, cliniques spécialisées, autres), canal de distribution (vente au détail, appel d'offres direct) - Tendances et prévisions de l'industrie jusqu'en 2029.
Analyse et perspectives du marché
Le marché des taxanes au Moyen-Orient et en Afrique devrait connaître une croissance du marché au cours de la période de prévision de 2022 à 2029. Data Bridge Market Research analyse que le marché croît avec un TCAC de 5,4% au cours de la période de prévision de 2022 à 2029. Les avancées technologiques dans les traitements médicamenteux aux taxanes, associées aux applications croissantes du diagnostic assisté par ordinateur, sont d'autres facteurs qui stimulent la croissance du marché des taxanes au cours de la période de prévision.
Cependant, le coût élevé associé au médicament et les effets secondaires tels que les caillots sanguins, la leucopénie, les allergies, la diarrhée et la perte de poids freineront la croissance du marché. L'adoption d'alliances stratégiques telles que les partenariats et les acquisitions par des acteurs clés du marché constitue une opportunité pour la croissance du marché des taxanes.
Rapport métrique |
Détails |
Période de prévision |
2022 à 2029 |
Année de base |
2021 |
Années historiques |
2020 |
Unités quantitatives |
Chiffre d'affaires en millions USD, prix en USD |
Segments couverts |
Par type (paclitaxel, docétaxel et cabazitaxel), type de médicament (de marque et génériques), formulation (liposomes et micelles polymères contenant des taxanes, formulations d'hydrogels de taxanes, formulation de nanoparticules et autres), groupe d'âge (adultes et gériatriques), application (cancer de l'ovaire, cancer du sein, cancer de la prostate, cancer du poumon non à petites cellules et autres), utilisateur final (hôpitaux, centres de chirurgie ambulatoire , cliniques spécialisées et autres), canal de distribution (appel d'offres direct, vente au détail) |
Pays couverts |
Arabie saoudite, Émirats arabes unis, Égypte, Israël, Afrique du Sud, Koweït et reste du Moyen-Orient et de l'Afrique |
Acteurs du marché couverts |
Viatris Inc., Sandoz International GmbH (une division de Novartis), sanofi-aventis US LLC, Hikma Pharmaceuticals PLC, Pfizer Inc., Dr. Reddy's Laboratories Ltd., Taxane Healthcare, Bristol-Myers Squibb Company, Fresenius Kabi AG (filiale de Fresenius SE & Co. KGaA), SAMYANG HOLDINGS CORPORATION., Luye Pharma Group, Elevar Therapeutics, Huiang Pharmaceutical Co Ltd., Shenzhen Main Luck Pharmaceuticals Inc., Accord Healthcare, Torrent Pharmaceuticals Ltd., Panacea Biotec, RPG Life Sciences Limited., Aureate Healthcare, Samarth Life Sciences Pvt. Ltd., Cipla Inc., Hetero Healthcare Limited., AqVida GmbH, Ingenus Pharmaceuticals, LLC, entre autres. |
Définition du marché des taxanes
The taxanes or taxoids are a closely related group of antineoplastic agents that have a unique mechanism of action as mitosis inhibitors and are widely used in the therapy of ovarian, breast, lung, esophageal, prostate, bladder and head and neck cancers. Three taxanes are in clinical use, paclitaxel (Taxol: 1992), docetaxel (Taxotere: 1996) and cabazitaxel (Jevtana: 2010). Taxanes are anticancer drugs that interfere with microtubule function, causing changes in mitosis and cellular death. Paclitaxel (Taxol) was first isolated from a yew tree, a small evergreen coniferous tree with a slow growth rate. As paclitaxel was initially scarce, docetaxel (Taxotere), a semisynthetic analogue of paclitaxel derived from the needles of the European yew tree Taxus baccata, was created. Docetaxel differs from paclitaxel in two chemical locations, making it more water soluble. Cabazitaxel is also a semisynthetic analogue of natural taxoids and was developed for its lack of affinity for P-glycoprotein, a common mediator of docetaxel resistance.
Furthermore, increasing use of taxane drugs due to rising prevalence of chronic diseases, surging prevalence of cancer, and increasing investment for healthcare infrastructure. These factors increase in the demand for taxane market has encouraged the key market players to implement newer technologies and strategies through product launches, acquisition, strategies and agreements.
Taxane Market Dynamics
Drivers
- The rise in incidence of cancer
Cancer has a major impact on society in the United States and worldwide. Cancer statistics describe what happens in large groups of people and provide a picture in time of the burden of cancer on society. Taxol, an antimitotic agent, used to treat cancer, blocks cancer cell growth by stopping cell division, resulting in cell death.
According to National Cancer Institute (NCI), a funded clinical trial found that 30 percent of patients with advanced ovarian cancer responded positively to taxane treatment. In clinical practice, the taxane is now standard therapy in metastatic breast cancer. Today, taxol is on the World Health Organization's Model List of Essential Medicines, a cytotoxic drug that kills cancer cells. It treats breast cancer, ovarian cancer, non-small cell lung cancer, pancreatic cancer, and AIDS-related Kaposi sarcoma.
- The funding by the government and investment in research and development
Despite the established effectiveness of pharmacotherapies for treating opioid use and alcohol disorders, limitations to the implementation of taxane by specialty treatment programs have been observed. Certain attention needs to be paid to specific sources for funding, organizational structure, and workforce resources, making a long-term investment that aligns the payment with the potential future beneficiaries. The issues around sustainability, productivity, and patient impact of drug development have never been and will not simply be a product of industry.
The funding by the government would result in the patient's safety, cost-savings. In addition, hospitals and healthcare agencies would administer this treatment at a lower price through collaboration with government organizations. Hence the advancements in research and development activities and funding by the government are expected to drive the market growth.
Restraint
-
Side effects of drugs incurred with the taxane drugs
Taxanes belong to a class of diterpenes. Taxane drugs (paclitaxel and docetaxel) are used as chemotherapeutic agents. Due to ongoing clinical trials, research studies, type of cancer, type of treatment plan, and drug dosage, the present high cost is expected to show a descending trend in the future. Taxane drugs are most effective for treating breast and prostate cancer. However, certain side effects have been reported. The adverse complications or side effects reported would lead to a decline in sales of the taxane drugs, which would limit the sales of the drugs. In addition, it would affect the reliability of manufacturers involved in this market and hence be expected to restrain the market growth.
Opportunity
-
Strategic initiative by market players
The demand for taxane market has increased in the U.S. and Europe owing to the timely treatment of alcohol and opioid disorders. These favorable factors enhance the need for taxane, and to achieve the market demand, minor and major market players are utilizing various strategies.
The major players are also trying to devise specific strategies, such as product launches, acquisitions, approvals, expansions, and partnerships, to ensure the smooth running of the business, avoid risks, and increase the long-term growth in the sales of the market.
These strategic initiatives by the market players, including acquisition, conferences, and focused segment product launches, are helping the companies grow and improve the company's product portfolios, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players provide an opportunity to help in future growth and drive market growth.
Challenge
- The lack of skilled professionals required for taxane drug treatment
The lack or shortage of skilled expertise would challenge the pace of recovery and growth in one place. Often the unemployed people in one place have skills that are in short supply elsewhere. Moreover, rapid technological advancement in this field also leads to a lack of expertise.
Physician supply is a term used to describe the number of trained physicians working in a healthcare system or labor market. It is dependent on the number of graduates and the retention rates of the profession. The physician shortage is a growing concern in many countries around the world.
The World Health Organization (WHO) estimated a global shortage of 4.3 million physicians, nurses, and other health professionals. Despite the strong evidence for the effectiveness of drugs in reducing morbidity and mortality, increasing treatment retention, and improving well-being for individuals with taxane, numerous barriers prevent broader access to taxane drug-based treatment.
Moreover, technological advancement is another aspect that leads to the increased demand for skilled professionals. Neurologists report significant unmet supportive care needs and barriers in their centers, with only a small minority rating themselves as competently providing supportive care. There is an urgent need for the education of professionals for the treatment of dementia and procuring available supportive care resources. Lack of trained and experienced professionals and persistent skill gaps limit the employability prospects and access to quality jobs. Therefore, it is apparent that the availability of professionals with adequate skills is challenging the market growth.
Post COVID-19 Impact on Taxane Market
COVID-19 has resulted in a substantial increase in demand for medical supplies from healthcare professionals and the general public for precautionary measures. Manufacturers of these items have an opportunity to take advantage of the increased demand for medical supplies by ensuring a steady supply of personal protective equipment on the market. COVID-19 is anticipated to have a big impact on the taxane market.
Recent Developments
- In November 2022, Viatris Inc. and Biocon Biologics Ltd. announced the U.S. launch of interchangeable biosimilars SEMGLEE (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine (insulin glargine-yfgn) injection, an unbranded product, to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. Both biosimilar products are available in vial and prefilled pen presentations and are interchangeable for the reference brand, LANTUS (insulin glargine), allowing for substitution at the pharmacy counter. Viatris is committed to improving patient access to sustainable, quality and more affordable healthcare. This has helped the company to grow their product portfolio.
- In May 2022, Sandoz, a global leader in generic and biosimilar medicines, announced the U.S. launch of its generic pirfenidone, the first AB-rated (fully substitutable) equivalent to Genentech’s Esbriet, to treat patients with idiopathic pulmonary fibrosis (IPF). This prescription oral medicine is immediately available to patients via specialty pharmacies, with a $0 co-pay program for eligible patients. Sandoz is putting patients first by expanding access to generic pirfenidone for those with this rare disease, who will benefit from a more affordable, yet equally effective treatment. This has helped the company to grow its market position and business.
Taxane Scope and Market Size
Taxane market is segmented based on type, drug type, formulation, age group, application, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the Difference in your target markets.
By Type
- Paclitaxel
- Docetaxel
- Cabazitaxel
On the basis of type, the Middle East and Africa taxane market is segmented into paclitaxel, docetaxel and cabazitaxel.
By Application
- Ovarian Cancer
- Breast Cancer
- Prostate Cancer
- Non-small Cell Lung Cancer
- Other
On the basis of application, the Middle East and Africa taxane market is segmented into ovarian cancer, breast cancer, prostate cancer, non-small cell lung cancer and others.
By Drug Type
- Generics
- Branded
On the basis of drug type, the Middle East and Africa taxane market is segmented into branded and generics.
By Formulation
- Liposomes
- Nanoparticles
- Polymeric Micelles
- Others
On the basis of formulation, the Middle East and Africa taxane market is segmented into liposomes, nanoparticles, polymeric micelles and others.
By Age Group
- Adult
- Geriatric
On the basis of age group, the Middle East and Africa taxane market is segmented into adults and geriatric.
By End User
- Hospitals
- Ambulatory surgical centers
- Specialty clinics
- Others
On the basis of end user, the Middle East and Africa taxane market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and others.
By Distribution Channel
- Direct tender
- Retail Sales
On the basis of distribution channel, the Middle East and Africa taxane market is segmented into direct tender, retail sales.
Middle East and Africa Taxane Market Regional Analysis
The taxane market is analyzed and market size information is provided by type, drug type, formulation, age group, application, end user and distribution channel.
The countries covered in the taxane market report are Saudi Arabia, U.A.E, Egypt, Israel, South Africa, Kuwait & rest of Middle East and Africa.
In 2022, South Africa is dominating due to the presence of key market players along the largest consumer market with high GDP. South Africa is expected to grow due to rise in technological advancement in drug treatments.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Le marché des taxanes vous fournit également une analyse de marché détaillée pour la croissance de chaque pays dans le secteur de la santé. De plus, il fournit des informations détaillées sur les services et traitements de santé, l'impact des scénarios réglementaires et les paramètres de tendance concernant le marché des taxanes.
Analyse du paysage concurrentiel et des parts de marché des taxanes
Le paysage concurrentiel du marché des taxanes fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les pipelines d'essais de produits, les approbations de produits, les brevets, la largeur et l'ampleur du produit, la domination des applications, la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise vers les médicaments à base de taxanes.
Français Les principales entreprises qui opèrent sur le marché des taxanes sont Viatris Inc., Sandoz International GmbH (une division de Novartis), sanofi-aventis US LLC, Hikma Pharmaceuticals PLC, Pfizer Inc., Dr. Reddy's Laboratories Ltd., Taxane Healthcare, Bristol-Myers Squibb Company, Fresenius Kabi AG (filiale de Fresenius SE & Co. KGaA), SAMYANG HOLDINGS CORPORATION., Luye Pharma Group, Elevar Therapeutics, Huiang Pharmaceutical Co Ltd., Shenzhen Main Luck Pharmaceuticals Inc., Accord Healthcare, Torrent Pharmaceuticals Ltd., Panacea Biotec, RPG Life Sciences Limited., Aureate Healthcare, Samarth Life Sciences Pvt. Ltd., Cipla Inc., Hetero Healthcare Limited., AqVida GmbH, Ingenus Pharmaceuticals, LLC entre autres.
Les alliances stratégiques telles que les fusions, les acquisitions et les accords entre les principaux acteurs du marché devraient également accélérer la croissance des médicaments à base de taxanes.
La collaboration, le lancement de produits, l'expansion commerciale, les récompenses et la reconnaissance, les coentreprises et d'autres stratégies des acteurs du marché améliorent l'empreinte de l'entreprise sur le marché des taxanes, ce qui offre également l'avantage de la croissance des bénéfices de l'organisation.
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. Les données du marché sont analysées et estimées à l'aide de modèles statistiques et cohérents du marché. En outre, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. La principale méthodologie de recherche utilisée par l'équipe de recherche DBMR est la triangulation des données, qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). En dehors de cela, les modèles de données comprennent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement de l'entreprise, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse des parts de marché du Moyen-Orient et de l'Afrique par rapport aux régions et des fournisseurs. Veuillez demander un appel à l'analyste en cas de demande de renseignements supplémentaires.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA TAXANE MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL_ANALYSIS
4.2 PORTER'S FIVE FORCES MODEL
5 EPIDEMIOLOGY
6 INDUSTRIAL INSIGHTS
6.1 CONCLUSION
7 MIDDLE EAST & AFRICA TAXANE MARKET: REGULATIONS
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 THE RISE IN INCIDENCE OF CANCER
8.1.2 THE FUNDING BY THE GOVERNMENT AND INVESTMENT IN RESEARCH AND DEVELOPMENT
8.1.3 RISE IN PIPELINE OR CLINICAL TRIALS OF TAXANE TREATMENTS
8.1.4 USE OF REIMBURSEMENT FOR TAXANE
8.2 RESTRAINTS
8.2.1 SIDE EFFECTS OF DRUGS INCURRED WITH THE TAXANE DRUGS
8.2.2 ETHICAL ISSUES RELATED TO THE USE OF TAXANE TREATMENT
8.2.3 RISE IN PRODUCT RECALLS
8.3 OPPORTUNITIES
8.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS
8.3.2 RISE IN HEALTHCARE EXPENDITURE
8.4 CHALLENGES
8.4.1 THE LACK OF SKILLED PROFESSIONALS REQUIRED FOR TAXANE DRUG TREATMENT
8.4.2 STRINGENT GOVERNMENT REGULATIONS ON TAXANE DRUG TREATMENT
9 MIDDLE EAST & AFRICA TAXANE MARKET, BY TYPE
9.1 OVERVIEW
9.2 PACLITAXEL
9.2.1 BY TYPE
9.2.1.1 SEMI-SYNTHETIC
9.2.1.2 NATURAL
9.2.2 BY STRENGTH
9.2.2.1 100MG
9.2.2.2 200MG
9.2.2.3 250MG
9.2.2.4 30MG
9.2.2.5 260MG
9.2.2.6 300MG
9.3 DOCETAXEL
9.3.1 120MG
9.3.2 80MG
9.3.3 20MG
9.3.4 40MG
9.3.5 60MG
9.4 CABAZITAXEL
9.4.1 60MG
10 MIDDLE EAST & AFRICA TAXANE MARKET, BY APPLICATION
10.1 OVERVIEW
10.2 BREAST CANCER
10.3 NON-SMALL CELL LUNG CANCER
10.4 PANCREATIC CANCER
10.5 OVARIAN CANCER
10.6 PROSTATE CANCER
10.7 OTHERS
11 MIDDLE EAST & AFRICA TAXANE MARKET, BY DRUG TYPE
11.1 OVERVIEW
11.2 GENERICS
11.3 BRANDED
12 MIDDLE EAST & AFRICA TAXANE MARKET, BY FORMULATION
12.1 OVERVIEW
12.2 LIPOSOMES
12.3 NANOPARTICLES
12.4 POLYMERIC MICELLES
12.5 OTHERS
13 MIDDLE EAST & AFRICA TAXANE MARKET, BY AGE GROUP
13.1 OVERVIEW
13.2 ADULT
13.2.1 FEMALE
13.2.2 MALE
13.3 GERIATRIC
13.3.1 FEMALE
13.3.2 MALE
14 MIDDLE EAST & AFRICA TAXANE MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 AMBULATORY SURGICAL CENTERS
14.4 SPECIALTY CLINICS
14.5 OTHERS
15 MIDDLE EAST & AFRICA TAXANE MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 RETAIL SALES
15.2.1 HOSPITAL PHARMACY
15.2.2 RETAIL PHARMACY
15.2.3 ONLINE PHARMACY
15.3 DIRECT TENDER
16 MIDDLE EAST & AFRICA TAXANE MARKET, BY REGION
16.1 MIDDLE EAST AND AFRICA
16.1.1 SOUTH AFRICA
16.1.2 EGYPT
16.1.3 SAUDI ARABIA
16.1.4 U.A.E
16.1.5 ISRAEL
16.1.6 KUWAIT
16.1.7 REST OF MIDDLE EAST AND AFRICA
17 MIDDLE EAST & AFRICA TAXANE MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 BRISTOL-MYERS SQUIBB COMPANY
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 SANOFI-AVENTIS U.S. LLC
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 VIATRIS INC.
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 SANDOZ INTERNATIONAL GMBH (A NOVARTIS DIVISION)
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 FRESENIUS KABI AG (SUBSIDIARY OF FRESENIUS SE & CO. KGAA )
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 HIKMA PHARMACEUTICALS PLC
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENTS
19.7 ACCORD HEALTHCARE
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENTS
19.8 AQVIDA GMBH
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENTS
19.9 AUREATE HEALTHCARE
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENTS
19.1 CIPLA INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENTS
19.11 DR. REDDY’S LABORATORIES LTD.
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 ELEVAR THERAPEUTICS
19.12.1 COMPANY SNAPSHOT
19.12.2 PRODUCT PORTFOLIO
19.12.3 RECENT DEVELOPMENTS
19.13 HETERO HEALTHCARE LIMITED.
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENTS
19.14 HUIANG PHARMACEUTICAL CO LTD
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENTS
19.15 INGENUS PHARMACEUTICALS, LLC
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENTS
19.16 LUYE PHARMA GROUP
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENTS
19.17 PANACEA BIOTEC
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENTS
19.18 PFIZER INC.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENTS
19.19 RPG LIFE SCIENCES LIMITED
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUE ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENTS
19.2 SAMARTH LIFE SCIENCES PVT. LTD.
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENTS
19.21 SAMYANG HOLDINGS CORPORATION.
19.21.1 COMPANY SNAPSHOT
19.21.2 REVENUE ANALYSIS
19.21.3 PRODUCT PORTFOLIO
19.21.4 RECENT DEVELOPMENTS
19.22 SHENZHEN MAIN LUCK PHAR MACEUTICALS INC.
19.22.1 COMPANY SNAPSHOT
19.22.2 PRODUCT PORTFOLIO
19.22.3 RECENT DEVELOPMENTS
19.23 TORRENT PHARMACEUTICALS LTD
19.23.1 COMPANY SNAPSHOT
19.23.2 REVENUE ANALYSIS
19.23.3 PRODUCT PORTFOLIO
19.23.4 RECENT DEVELOPMENTS
19.24 TAXANE HEALTHCARE
19.24.1 COMPANY SNAPSHOT
19.24.2 PRODUCT PORTFOLIO
19.24.3 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
Liste des tableaux
TABLE 1 MIDDLE EAST & AFRICA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 2 MIDDLE EAST & AFRICA PACLITAXEL IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA DOCETAXEL IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA CABAZITAXEL IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA BREAST CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA NON-SMALL LUNG CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA PANCREATIC CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA OVARIAN CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA PROSTATE CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA OTHERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA GENERICS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA BRANDED IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA LIPOSOMES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA NANOPARTICLES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA POLYMERIC MICELLES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA OTHERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA ADULT IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA GERIATRIC IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA HOSPITALS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA SPECIALTY CLINICS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA OTHERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA RETAIL SALES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA DIRECT TENDER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA TAXANE MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 53 SOUTH AFRICA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 SOUTH AFRICA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 SOUTH AFRICA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 56 SOUTH AFRICA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 57 SOUTH AFRICA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 58 SOUTH AFRICA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 59 SOUTH AFRICA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 60 SOUTH AFRICA CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 61 SOUTH AFRICA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 62 SOUTH AFRICA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 63 SOUTH AFRICA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 64 SOUTH AFRICA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 65 SOUTH AFRICA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 66 SOUTH AFRICA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 67 EGYPT TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 68 EGYPT PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 69 EGYPT TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 70 EGYPT TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 71 EGYPT TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 72 EGYPT PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 73 EGYPT DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 74 EGYPT CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 75 EGYPT TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 76 EGYPT ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 77 EGYPT GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 78 EGYPT TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 79 EGYPT TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 80 EGYPT RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 81 SAUDI ARABIA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 SAUDI ARABIA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 83 SAUDI ARABIA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 84 SAUDI ARABIA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 85 SAUDI ARABIA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 86 SAUDI ARABIA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 87 SAUDI ARABIA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 88 SAUDI ARABIA CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 89 SAUDI ARABIA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 90 SAUDI ARABIA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 91 SAUDI ARABIA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 92 SAUDI ARABIA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 93 SAUDI ARABIA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 94 SAUDI ARABIA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 95 U.A.E TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 96 U.A.E PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 97 U.A.E TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 98 U.A.E TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 99 U.A.E TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 100 U.A.E PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 101 U.A.E DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 102 U.A.E CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 103 U.A.E TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 104 U.A.E ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 105 U.A.E GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 106 U.A.E TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 107 U.A.E TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 108 U.A.E RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 109 ISRAEL TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 110 ISRAEL PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 111 ISRAEL TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 112 ISRAEL TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 113 ISRAEL TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 114 ISRAEL PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 115 ISRAEL DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 116 ISRAEL CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 117 ISRAEL TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 118 ISRAEL ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 119 ISRAEL GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 120 ISRAEL TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 121 ISRAEL TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 122 ISRAEL RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 123 KUWAIT TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 124 KUWAIT PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 125 KUWAIT TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 126 KUWAIT TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 127 KUWAIT TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 128 KUWAIT PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 129 KUWAIT DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 130 KUWAIT CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 131 KUWAIT TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 132 KUWAIT ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 133 KUWAIT GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 134 KUWAIT TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 135 KUWAIT TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 136 KUWAIT RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 137 REST OF MIDDLE EAST AND AFRICA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
Liste des figures
FIGURE 1 MIDDLE EAST & AFRICA TAXANE MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA TAXANE MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA TAXANE MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA TAXANE MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA TAXANE MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA TAXANE MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA TAXANE MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 MIDDLE EAST & AFRICA TAXANE MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST & AFRICA TAXANE MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA TAXANE MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE MIDDLE EAST & AFRICA TAXANE MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASING INVESTMENT FOR HEALTHCARE INFRASTRUCTURE IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA TAXANE MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 THE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA TAXANE MARKET IN 2022 & 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA TAXANE MARKET
FIGURE 15 INCIDENCE OF BREAST CANCER IN 2020
FIGURE 16 MIDDLE EAST & AFRICA TAXANE MARKET: BY TYPE, 2021
FIGURE 17 MIDDLE EAST & AFRICA TAXANE MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 18 MIDDLE EAST & AFRICA TAXANE MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 19 MIDDLE EAST & AFRICA TAXANE MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 MIDDLE EAST & AFRICA TAXANE MARKET: BY APPLICATION, 2021
FIGURE 21 MIDDLE EAST & AFRICA TAXANE MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 22 MIDDLE EAST & AFRICA TAXANE MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 23 MIDDLE EAST & AFRICA TAXANE MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 24 MIDDLE EAST & AFRICA TAXANE MARKET: BY DRUG TYPE, 2021
FIGURE 25 MIDDLE EAST & AFRICA TAXANE MARKET: BY DRUG TYPE, 2022-2029 (USD MILLION)
FIGURE 26 MIDDLE EAST & AFRICA TAXANE MARKET: BY DRUG TYPE, CAGR (2022-2029)
FIGURE 27 MIDDLE EAST & AFRICA TAXANE MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 28 MIDDLE EAST & AFRICA TAXANE MARKET: BY FORMULATION, 2021
FIGURE 29 MIDDLE EAST & AFRICA TAXANE MARKET: BY FORMULATION, 2022-2029 (USD MILLION)
FIGURE 30 MIDDLE EAST & AFRICA TAXANE MARKET: BY FORMULATION, CAGR (2022-2029)
FIGURE 31 MIDDLE EAST & AFRICA TAXANE MARKET: BY FORMULATION, LIFELINE CURVE
FIGURE 32 MIDDLE EAST & AFRICA TAXANE MARKET: BY AGE GROUP, 2021
FIGURE 33 MIDDLE EAST & AFRICA TAXANE MARKET: BY AGE GROUP, 2022-2029 (USD MILLION)
FIGURE 34 MIDDLE EAST & AFRICA TAXANE MARKET: BY AGE GROUP, CAGR (2022-2029)
FIGURE 35 MIDDLE EAST & AFRICA TAXANE MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 36 MIDDLE EAST & AFRICA TAXANE MARKET: BY END USER, 2021
FIGURE 37 MIDDLE EAST & AFRICA TAXANE MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 38 MIDDLE EAST & AFRICA TAXANE MARKET: BY END USER, CAGR (2022-2029)
FIGURE 39 MIDDLE EAST & AFRICA TAXANE MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 MIDDLE EAST & AFRICA TAXANE MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 41 MIDDLE EAST & AFRICA TAXANE MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 42 MIDDLE EAST & AFRICA TAXANE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 43 MIDDLE EAST & AFRICA TAXANE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 MIDDLE EAST AND AFRICA TAXANE MARKET: SNAPSHOT (2021)
FIGURE 45 MIDDLE EAST AND AFRICA TAXANE MARKET: BY COUNTRY (2021)
FIGURE 46 MIDDLE EAST AND AFRICA TAXANE MARKET: BY COUNTRY (2022 & 2029)
FIGURE 47 MIDDLE EAST AND AFRICA TAXANE MARKET: BY COUNTRY (2021 & 2029)
FIGURE 48 MIDDLE EAST AND AFRICA TAXANE MARKET: BY TYPE (2022-2029)
FIGURE 49 MIDDLE EAST & AFRICA TAXANE MARKET: COMPANY SHARE 2021 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.